Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?

Jacki Chen(Rutgers, The State University of New Jersey), Robert G. Gish(California Pacific Medical Center), Thomas Tu(The University of Sydney), Yao‐Chun Hsu(China Medical University), Chari Cohen(Hepatitis B Foundation), Su Wang(Rutgers, The State University of New Jersey)
Hepatology
December 26, 2023
10.1097/hep.0000000000000732
Cited by 2

Related Papers

Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver Resection
|JAMA|2012|827
Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy
|Cell stem cell|2016|565
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
|Journal of Hepatology|2019|364
Neonatal Chimerization with Human Glial Progenitor Cells Can Both Remyelinate and Rescue the Otherwise Lethally Hypomyelinated Shiverer Mouse
|Cell stem cell|2008|329
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
|Hepatology|2013|276